Neil Gunn
Fortuna: 538 382 $ al 31/05/2026
Fortuna: 538 382 $ al 31/05/2026
Dr. Neil Gunn is an Independent Director at NeoGenomics, Inc., an Independent Director at Rarecells, Inc. and an Independent Director at Alveo Technologies, Inc. He is on the Board of Directors at NeoGenomics, Inc., Rarecells, Inc., Alveo Technologies, Inc. and Rarecells Diagnostics SAS. Dr. Gunn was previously employed as a Chief Executive Officer & Director by IDbyDNA, Inc., a Non-Executive Director by Genetic Signatures Ltd., a President by Roche Sequencing Solutions, Inc., a Vice President-Commercial Operations by CaridianBCT, Inc., a Vice President-Commercial Operations by Novartis Vaccines & Diagnostics SL, and a Head-Global Business by Roche Molecular Systems, Inc. He received his undergraduate degree from Nottingham Trent University, a graduate degree from the University of Portsmouth and a doctorate degree from the University of Portsmouth.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
NEOGENOMICS, INC. 0,04 % | 01/06/2026 | 51.177 ( 0,04 % ) | 538 382 $ | 31/05/2026 |
| 08/05/2026 | 0 ( -.--% ) | - $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| NEOGENOMICS, INC. | Director/Miembro de la Junta | 26/06/2023 |
Alveo Technologies, Inc.
Alveo Technologies, Inc. Medical SpecialtiesHealth Technology Operates a pre-clinical stage medical diagnostics company that creates infectious disease diagnostic devices | Director/Miembro de la Junta | 13/05/2021 |
Rarecells USA, Inc.
Rarecells USA, Inc. Packaged SoftwareTechnology Services Develops and commercializes technology to isolate circulating cancer cells for early cancer diagnosis and medical research | Director/Miembro de la Junta | 06/09/2022 |
Rarecells Diagnostics SAS
Rarecells Diagnostics SAS Packaged SoftwareTechnology Services Develops and commercializes ISET technology to isolate circulating cancer cells for early cancer diagnosis & medical research | Director/Miembro de la Junta | - |
| Empresas | Cargo | Fin |
|---|---|---|
| GENETIC SIGNATURES LIMITED | Director Ejecutivo | 30/09/2024 |
IDbyDNA, Inc.
IDbyDNA, Inc. BiotechnologyHealth Technology Develops technologies that will enable nucleic acid based identification testing services | Director Ejecutivo | 01/01/2022 |
CaridianBCT, Inc.
CaridianBCT, Inc. Medical/Nursing ServicesHealth Services Designs, develops and supplies blood components | Corporate Officer/Principal | - |
Novartis Vaccines & Diagnostics SL | Corporate Officer/Principal | - |
Roche Molecular Systems, Inc.
Roche Molecular Systems, Inc. Medical/Nursing ServicesHealth Services Develops & produces molecular-based diagnostic tests & automated testing platforms | Corporate Officer/Principal | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 12 |
|---|---|
NeoGenomics, Inc.
NeoGenomics, Inc. Medical/Nursing ServicesHealth Services Provides genetic and molecular testing services | Health Services |
Nottingham Trent University
Nottingham Trent University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
CaridianBCT, Inc.
CaridianBCT, Inc. Medical/Nursing ServicesHealth Services Designs, develops and supplies blood components | Health Services |
Genetic Signatures Ltd.
Genetic Signatures Ltd. Miscellaneous Commercial ServicesCommercial Services Develops and commercializes diagnostic kits | Commercial Services |
University of Portsmouth
University of Portsmouth Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Roche Molecular Systems, Inc.
Roche Molecular Systems, Inc. Medical/Nursing ServicesHealth Services Develops & produces molecular-based diagnostic tests & automated testing platforms | Health Services |
Novartis Vaccines & Diagnostics SL | |
Rarecells USA, Inc.
Rarecells USA, Inc. Packaged SoftwareTechnology Services Develops and commercializes technology to isolate circulating cancer cells for early cancer diagnosis and medical research | Technology Services |
IDbyDNA, Inc.
IDbyDNA, Inc. BiotechnologyHealth Technology Develops technologies that will enable nucleic acid based identification testing services | Health Technology |
Alveo Technologies, Inc.
Alveo Technologies, Inc. Medical SpecialtiesHealth Technology Operates a pre-clinical stage medical diagnostics company that creates infectious disease diagnostic devices | Health Technology |
Roche Sequencing Solutions, Inc.
Roche Sequencing Solutions, Inc. Medical/Nursing ServicesHealth Services Provides diagnostics and treatments services | Health Services |
Rarecells Diagnostics SAS
Rarecells Diagnostics SAS Packaged SoftwareTechnology Services Develops and commercializes ISET technology to isolate circulating cancer cells for early cancer diagnosis & medical research | Technology Services |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.